Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orhan Sezer

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 27, 2006
Angiogenesis in multiple myelomaChristian Jakob, Jan Sterz, Ivana Zavrski, et al.
Journal of Cancer Research and Clinical Oncology|April 18, 2003
Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-IIIKathrin Niemöller, Christian Jakob, Ulrike Heider, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 25, 2002
Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapyLutz Liefeldt, Martin Buhl, Britta Schweickert, et al.
Investigational New Drugs|July 14, 2005
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-studyPeter Schmid, Bernd Flath, Konstantin Akrivakis, et al.
European Journal of Haematology|February 18, 2009
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphomaUlrike Heider, Jessica Rademacher, Britta Lamottke, et al.
Haematologica|February 8, 2006
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myelomaMartin Kaiser, Ivana Zavrski, Jan Sterz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patientsPierre-Benoit Tremblay, Rolf Kaiser, Orhan Sezer, et al.
Expert Opinion on Investigational Drugs|May 22, 2008
The potential of proteasome inhibitors in cancer therapyJan Sterz, Ivana von Metzler, Jens-Claus Hahne, et al.
Anti-Cancer Drugs|April 23, 2005
Proteasome: an emerging target for cancer therapyIvana Zavrski, Christian Jakob, Peter Schmid, et al.
European Journal of Haematology|December 14, 2005
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphomaUlrike Heider, Martin Kaiser, Jan Sterz, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|June 27, 2006
Angiogenesis in multiple myelomaChristian Jakob, Jan Sterz, Ivana Zavrski, et al.
Journal of Cancer Research and Clinical Oncology|April 18, 2003
Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-IIIKathrin Niemöller, Christian Jakob, Ulrike Heider, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 25, 2002
Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapyLutz Liefeldt, Martin Buhl, Britta Schweickert, et al.
Investigational New Drugs|July 14, 2005
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-studyPeter Schmid, Bernd Flath, Konstantin Akrivakis, et al.
European Journal of Haematology|February 18, 2009
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphomaUlrike Heider, Jessica Rademacher, Britta Lamottke, et al.
Haematologica|February 8, 2006
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myelomaMartin Kaiser, Ivana Zavrski, Jan Sterz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patientsPierre-Benoit Tremblay, Rolf Kaiser, Orhan Sezer, et al.
Expert Opinion on Investigational Drugs|May 22, 2008
The potential of proteasome inhibitors in cancer therapyJan Sterz, Ivana von Metzler, Jens-Claus Hahne, et al.
Anti-Cancer Drugs|April 23, 2005
Proteasome: an emerging target for cancer therapyIvana Zavrski, Christian Jakob, Peter Schmid, et al.
European Journal of Haematology|December 14, 2005
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphomaUlrike Heider, Martin Kaiser, Jan Sterz, et al.
Pageof 11